Sarepta Therapeutic (SRPT) Data 'In-Line', Roth Capital Says

Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying today's data was in-line with expectations.

The analyst commented, "Data inline with expectations demonstrating: Significant functional gains (+151m 6MWT benefit) over 36 months vs. appropriate age, baseline, background therapy-matched control on the ITT population; fourth biopsy highlighting consistent dystrophin (100% showing exon-skipping, ~90% with dystrophin+ fibers, and ~82% with +WB) all performed with comprehensive guidance from the FDA; re-validation/re-scoring of prior dystrophin data; and robust safety (N=72). Risk/reward compelling and favors a positive panel vote and conditional approval."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $32.11 yesterday.

You May Also Be Interested In

• JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
• MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs
• Freedom Broker Starts Copart (CPRT) at Buy